GLP1R and Hepatic fibrosis: Dwinata and Gracen found that patients using sodium-glucose co-transporter 2 inhibitors (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP1Ra) have less incidences of diagnosed liver fibrosis [30,31].